Lymphatic system

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Retrieved on: 
목요일, 4월 18, 2024
Eurostat, Diagnosis, Civil service commission, X-ray, Growth, Medicine, Disease, Patient, Ageing, Committee, Knowledge, Tissue, Neoplasm, Light, Cutaneous T-cell lymphoma, Regulation, Cancer, EMA, IRIS, Quality of life, Reactive oxygen species, Lymph, CTCL, Clinical trial, European, Skin, COMP, Oxygen, European Commission, Immune system, Safety, Carmustine, Alfa, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Key Points: 


Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
화요일, 4월 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
화요일, 4월 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
목요일, 3월 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
목요일, 3월 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Retrieved on: 
수요일, 4월 3, 2024
Community, Civil service commission, Eurostat, Sneeze, Diagnosis, Granuloma, Cough, Prevalence, Cell, Disease, Infection, Tuberculosis, Central nervous system, Patient, Committee, Knowledge, Seriousness, Regulation, Bacteria, Meningitis, EMA, MDR TB, IRIS, Joint, Antimycobacterial, Periodic breathing, MDR, European, Fever, COMP, Safety, European Commission, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Key Points: 


Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
수요일, 3월 6, 2024
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Peripheral edema, Thoracic duct, Acute decompensated heart failure, Ohio State University, Physiology, Drainage, Congestion, Heart failure, ADHF, Cell biology, Death, Patient, Lymphatic system, Medicine, THT, Tissue, Pharmaceutical industry

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

La Jolla Vein & Vascular Proudly Announces World Lymphedema Day Patient Education Event

Retrieved on: 
수요일, 3월 6, 2024
Health, General Health, Caregiver, Multimedia, Education, Conditional sentence, Physician, Lymphedema, Quality of life, Learning, Patient, Lymphatic system, Nursing

La Jolla Vein & Vascular, a leading provider of vascular health services in the San Diego area, is excited to announce their upcoming event today, the World Lymphedema Day Patient Education Event.

Key Points: 
  • La Jolla Vein & Vascular, a leading provider of vascular health services in the San Diego area, is excited to announce their upcoming event today, the World Lymphedema Day Patient Education Event.
  • View the full release here: https://www.businesswire.com/news/home/20240306096183/en/
    La Jolla Vein & Vascular staff prepare for World Lymphedema Day Patient Education Event.
  • "We are thrilled to support World Lymphedema Day and hold this Patient Education Event as part of our ongoing commitment to improving vascular health and raising awareness about conditions such as lymphedema," said Dr. Nisha Bunke, Medical Director at La Jolla Vein & Vascular.
  • Don't miss this unique opportunity to participate in the World Lymphedema Day Patient Education Event on March 6, 2024, at La Jolla Vein & Vascular.

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Retrieved on: 
목요일, 2월 22, 2024
Start-Up, Biotechnology, Alternative Medicine, Professional Services, Health, Cannabis, Pharmaceutical, Neurology, Mental Health, Natural Resources, Clinical Trials, Therapy, Anxiety, Capsule, Multimedia, KCL, Absorption, Blood, Schizophrenia, GRAS, AUC, Lung, Cmax, Risk, Hepatotoxicity, University, Innovation, SME, University of Oxford, THC, Disorder, Lymphatic system, DMF, Adipose tissue, Brain, Pharmaceutical industry

Quolet , a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) ( clinicaltrials.gov NCT05032807 ).

Key Points: 
  • Quolet , a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) ( clinicaltrials.gov NCT05032807 ).
  • Researchers at King’s College London partnered with the SEEK group to test whether its bioavailability could be improved by administering CBD in a novel patented lipid formulation.
  • This lipid formulation allows high doses of CBD (200mg) to be administered in capsules including only GRAS and/or pharmaceutical approved ingredients.
  • In one visit they were given the lipid-CBD, and in the other visit they were given standard CBD-only formulation.

Amorepacific Announces Positive Research Results of Fermented Ginseng in Skin Lymphatic Activation

Retrieved on: 
화요일, 2월 6, 2024
Multimedia, School, Cell, Research, Immune system, AI, Ageing, 3D, Observation, Mechanical, NPG Asia Materials, Mechanical engineering, Homeostasis, Skin, Human, Beauty, Lymphatic system, Platform supply vessel, Nature, Algorithm, Health, Korea University

SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ -- Amorepacific, in collaboration with the School of Mechanical Engineering at Korea University, has unveiled groundbreaking research demonstrating the impact of lymphatic activation on skin health and the potential skin lymphatic improvement through fermented ginseng ingredients. This research, introducing new possibilities for skin aging and homeostasis maintenance using Lab-on-a-chip technology, was published in 'NPG Asia Materials,' an international journal by the scientific journal Nature. (Paper Title: The advanced 3D lymphatic system for assaying the human cutaneous lymphangiogenesis in the microfluidic platform)

Key Points: 
  • SEOUL, South Korea, Feb. 6, 2024 /PRNewswire/ -- Amorepacific, in collaboration with the School of Mechanical Engineering at Korea University, has unveiled groundbreaking research demonstrating the impact of lymphatic activation on skin health and the potential skin lymphatic improvement through fermented ginseng ingredients.
  • In this research, they cultivated human-derived skin cells and 3D lymphatic forming cells under optimal conditions to create a Skin-Lymph-on-a-chip.
  • This enabled the replication of networks between human skin and lymphatic vessels, visually observing the impact of substances applied to the skin on lymphatic formation and activity.
  • The joint research team concluded that Lymphanax™ aids in forming healthy lymphatic vessels within the skin and strengthens the skin barrier through additional analysis, including AI algorithms.